Endothelin-1 is a 21-amino acid endothelial vasoconstrictor peptide that may be the physiological antagonist of endothelium-derived relaxing factor (EDRF). Endothelin-1 (10-11-3 x 10-7 M) evoked potent contractions of isolated internal mammary arteries, internal mammary veins, and saphenous veins, which were Received June 5, 1989; accepted November 15, 1989. ical antagonist of endothelium-derived relaxing factors (EDRFs).11-5 One of the factors, nitric oxide, is a potent vasodilator and inhibitor of platelet function and most likely accounts in large parts for endothelium-dependent relaxations evoked by acetylcholine and bradykinin.16-18 The interaction and relative potency of endothelium-derived contracting and relaxing factors may be important in the regulation of local blood flow in health and disease. The function of the endothelium and vascular smooth muscle differs in arteries and veins.12,13,19-22 Endothelium-dependent relaxations are less pronounced in veins compared with arteries,19,20,22 whereas endothelium-dependent contractions predominate in veins.2' However, the heterogeneity of endothelium-dependent responses among species13 limits the results obtained in animal blood vessels and necessitates experiments in human vascular tissue.20'22-24 The present study was designed to investigate the vascular effects of endothelin-1 in human blood vessels and its interaction with EDRF released under basal conditions and after stimulation with acetylcholine and bradykinin.
ical antagonist of endothelium-derived relaxing factors (EDRFs).11-5 One of the factors, nitric oxide, is a potent vasodilator and inhibitor of platelet function and most likely accounts in large parts for endothelium-dependent relaxations evoked by acetylcholine and bradykinin. [16] [17] [18] The interaction and relative potency of endothelium-derived contracting and relaxing factors may be important in the regulation of local blood flow in health and disease.
The function of the endothelium and vascular smooth muscle differs in arteries and veins.12,13,19-22 Endothelium-dependent relaxations are less pronounced in veins compared with arteries,19,20,22 whereas endothelium-dependent contractions predominate in veins.2' However, the heterogeneity of endothelium-dependent responses among species13 limits the results obtained in animal blood vessels and necessitates experiments in human vascular tissue.20 '22-24 The present study was designed to investigate the vascular effects of endothelin-1 in human blood vessels and its interaction with EDRF released under basal conditions and after stimulation with acetylcholine and bradykinin.
Materials and Methods
Internal mammary arteries and veins and saphenous veins were obtained intraoperatively. 20 All patients (mean age, 59±1 years; age range, years; 84% males, 16% females) underwent bypass surgery for coronary artery disease. The vessels were dissected, cut into rings (5 mm in length), and placed into modified Krebs-Ringer bicarbonate solution of the following composition (mM): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25.0, edetate calcium disodium 0.026, and glucose 11.1 (control solution).
During harvesting, extreme care was taken not to touch the inner surface of the blood vessels. During surgical preparation of the saphenous veins, the dilatation procedure was avoided to preserve the endothelial layer. The presence or absence of the endothelium was confirmed at the beginning of the experiment in each ring (contracted with 10-7-3 x 10`M norepinephrine) by a relaxation to acetylcholine or bradykinin (10-6 M) . In some rings, the endothelium was removed by intraluminal perfusion of the vessel with 0.5% 3-[(3-cholamidopropyl)dimethylamino]-1-propanesulfonate (CHAPS)25 for 60 seconds (mammary artery) or 90 seconds (saphenous vein) or mechanically.20,23 The rings were suspended in organ chambers filled with 25 ml control solution (370 C) aerated with 95% 02-5% CO2 and connected to force transducers (Statham Universal UC2, Gould, Cleveland, Ohio). Changes in isometric force were recorded. Before the experiment, the preparations were stretched to their optimal point of the lengthtension relation. 20 The following drugs were used (unless otherwise indicated, the drugs were obtained from Sigma Chemical, St. Louis, Missouri): acetylcholine chloride, bradykinin, CHAPS, endothelin-1 (Peptide, Osaka, Japan), L-norepinephrine bitartrate, SIN-1 (the active metabolite of molsidomine; Hoechst Pharmaceutical, Paris, France), and sodium nitroprusside. The concentrations of the drugs are expressed as final molar concentrations in the bath solution.
Nitric oxide gas (99.9% pure) was obtained from L'Air Liquide Belge, Antwerp, Belgium. A glass bulb (125 ml in volume) was flushed with helium to remove oxygen. The flask was then filled with nitric oxide gas and closed. Separate glass bulbs were filled with 100 ml double-distilled water deoxygenated with helium over 4 hours. 16 Appropriate volumes of nitric oxide gas were then injected into the water-filled gas bulbs, and the concentration of nitric oxide in the fluid was calculated, taking into account its solubility in water and air. All gas bulbs were interconnected in a closed gas-tight system to prevent any entry of oxygen (Arbor Ventil and Fitting AG, Niederrohrdorf, Switzerland). Nitric oxide was injected with gas-tight syringes (Hamilton, Kontron AG, Zurich, Switzerland) into the organ chamber near the suspended vessels.
Whenever possible, rings with and without endothelium of mammary arteries and veins and saphenous veins obtained from the same patients were studied in parallel. When concentration response curves were constructed, the drugs were added in a cumulative fashion except for nitric oxide gas (because of rapid breakdown and evaporation of the substance in the aerated organ chambers). Contractions are expressed as percent of the increase in tension induced by 100 mM KCl. The negative molar concentration of an agonist exhibiting 50% of the contraction to KCl (EC50 value) was calculated for each ring separately. To study endotheliumdependent relaxations, the rings were contracted with a maximal or half-maximal concentration of norepinephrine or endothelin-1, respectively. The relaxations are expressed as percent relaxation of the contraction induced by either norepinephrine or endothelin-1. The concentration of an agonist exhibiting 30% or 50% relaxation of that contraction was calculated for each ring and expressed as negative log molar (pD.). For analysis, the maximal relaxation (in percent), the pDx value, or the area under the concentration-response curve (in arbitrary units ranging from 0 to 1,000; i.e., the smaller the area, the greater the relaxation) was used. Data are given as mean±SEM. In all experiments, n equals the number of patients from whom the blood vessels were obtained. For statistical analysis, the t test for paired or unpaired observations and analysis of variance followed by Scheffe's test were used. A two-tailed value of p<O.05 was considered to indicate a statistical difference.
Results

Endothelin-1-Induced Contractions
In internal mammary arteries with endothelium, endothelin-1 (10-11-3x10-' M) evoked concentration-dependent contractions ( Figure 1 ). Endothelial removal enhanced the maximal response (3 x 10-7 M) but not the sensitivity (EC50) to the peptide ( Figure 2 ; n=9 and 8, p<O.05). The internal mammary vein exhibited a markedly enhanced sensitivity and maximal response to endothelin-1 ( Figure 1 ; n=8). EC50 averaged 6.3 x 10-1l M in the vein and 2.5 x 10-9 M in the artery (concentration shift, 6.3-fold;p<0.05); the maximal response was 123+8% and 87±5% of 100 mM KCl, respectively (p<O.O1). In the saphenous vein, endothelin-1 evoked similar contractions as in the artery (Figure 1 ; EC50, 4x 0-9 M; n=9; p=NS).
The maximal response averaged 101±6% of 100 mM KCl. In the veins, endothelium removal did not affect the response to the peptide ( Figure 2 ; n =9 and 8).
Endothelin-1 and EDRF
Internal mammary artery. In rings maximally contracted with endothelin-1, acetylcholine (10-9-10-M) completely reversed the contractions induced by the peptide (Figure 3 Exogenous nitric oxide relaxed mammary arteries with a similar potency as endogenous EDRF irrespective of whether the rings were contracted with a maximal or half-maximal concentration of endothelin-1 ( Figure 5 ; n=5 to 6). The response to nitric oxide did not differ, whether the arteries were precontracted with a half-maximal concentration of endothelin-1 or norepinephrine (Figure 6; n=5) .
In mammary artery rings that were contracted with norepinephrine (3 x 10`7 M), endothelin-1 (10-13_ i0`M) added on top of that contraction did not induce endothelium-dependent relaxations (n=3; data not shown).
Veins. In saphenous veins that were maximally contracted with endothelin-1, the relaxations induced by bradykinin (14±9% at 10-5 M) or acetylcholine (3±2% at i0`M) were severely blunted as compared with the artery (Figure 3 ; n=3 and 4, respectively; p<0.005 to 0.01). When contracted with a half-maximal concentration of endothelin-1, the relaxations to bradykinin were still markedly inhibited compared with preparations contracted with a half-maximal concentration of norepinephrine (Figure 4 ; pD30, 6.0+0.1 and 7.1±0.3; concentration shift, 13-fold; p<0.01; n=6).
Exogenous nitric oxide evoked potent relaxations of saphenous veins contracted with a half-maximal concentration of norepinephrine ( Figure 6 ; n =5). Indeed, the response was slightly enhanced compared with the artery (p<0.01). In contrast, in saphenous and internal mammary veins contracted with a maximal or a halfmaximal concentration of endothelin-1, the response to exogenous nitric oxide was severely blunted compared with those contracted with norepinephrine (Figures 5  and 6 ; n=4 and 5, respectively; p<0.005).
Endothelin-1 and Nitrovasodilators
The nitrocompound SIN-1 (10-9-10-5 M), the active metabolite of molsidomine, inhibited maximal contractions induced by endothelin-1 in the internal mammary artery (pD30, 8.0±1.0; maximal response, 100+0%; Figure 7; The saphenous vein, however, was much less sensitive to the peptide than the mammary vein. This may indicate a heterogeneity of the responsiveness to endothelin-1 not only between arteries and veins, but also within the human venous system. The fact that endothelin-1 dominates EDRF in the veins could be related to greater effects of endothelin-1 on venous vascular smooth muscle, to a reduced release of EDRF in the veins, and/or to a reduced responsiveness of veins to endogenous or exogenous nitrovasodilators. Differences in the contractile state of arteries and veins are unlikely to play a role, since endothelin-1 inhibited endotheli- um-dependent relaxations in saphenous veins both at maximal and half-maximal contractions to the peptide. In addition, the response to exogenous nitric oxide was also blunted in the internal mammary vein, which exhibited an enhanced responsiveness to endothelin-1, as much as in the saphenous vein, which responded in a manner similar to the artery. '36 In human blood vessels, endothelin-1 induced most sustained contractions. Therefore, the availability of a potent endogenous antagonist such as EDRF for prevention of vasospasm and eventually vascular occlusion appears important.13'14'37 Endothelin-1 is released by thrombin and transforming growth factor (3, which can be formed or released at sites where platelets are activated.1-3 If the production of endothelin-1 is locally stimulated in response to these platelet-derived substances, its effects would be fully antagonized by EDRF in the mammary artery but not in veins. 20, 38, 39 Indeed, thrombin and ADP, which is also released from aggregating platelets, can liberate EDRF in healthy human arteries; in veins, much less of the endogenous nitrate is released under these conditions.2022 Similarly, in atherosclerotic arteries in which the release of EDRF is blunted,35'36"40-42 endothelin-1 would be unopposed by the endogenous nitrate. The imbalance of the effects of EDRF and endothelin-1 in veins may be of great clinical importance for coronary bypass surgery. Increased platelet-vessel wall interaction has been implicated in vein graft occlusion, and platelet inhibitors are effective in increasing the patency of venous bypasses.43 Indeed, the dominance of EDRF in the mammary artery may contribute to the better shortterm and long-term patency and lower patient mortality of arterial grafts compared with venous grafts. [44] [45] [46] [47] Moreover, this study would indicate that nitrates are more efficacious in arterial grafts than in venous bypasses as therapeutic interventions aimed at antagonizing endothelin-1-induced vasoconstriction.
